The European Medicines Agency has recommended a suspension of marketing authorisations for medicinal products Tredaptive, Pelzont and Trevaclyn (nicotinic acid/laropiprant)
23.01.2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a suspension of marketing authorisations for medicinal products Tredaptive, Pelzont and Trevaclyn from the EU countries. The CHMP has concluded that the benefits of the aforementioned medicinal products no longer outweigh the risks of their use. The CHMP opinion will be forwarded to the European Commission for adoption of legally binding decisions. The medicinal products Tredaptive, Pelzont and Trevaclyn have never been placed on the Croatian market.
We remind healthcare professionals that they should report any adverse reaction to HALMED, as well as quality defect. Patients who have developed any adverse reaction to medicinal product may report it directly to HALMED via form or on-line application, with recommendation regarding any adverse reaction they discover to consult with their doctor or pharmacist about the continuation of their therapy.
